|Bid||6.05 x 100|
|Ask||0.00 x 0|
|Day's Range||7.22 - 7.46|
|52 Week Range||4.40 - 7.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In this analysis, my focus will be on developing a perspective on MediciNova Inc’s (NASDAQ:MNOV) latest ownership structure, a less discussed, but important factor. Ownership structure has been found toRead More...
Yuichi Iwaki took the reins as CEO of MediciNova Inc’s (NASDAQ:MNOV) and grew market cap to $252.71M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...
The latest earnings update MediciNova Inc’s (NASDAQ:MNOV) released in September 2017 revealed that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below isRead More...
After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past and compareRead More...
The primary endpoint of the study (safety and tolerability) was achieved and there were efficacy trends in key functional secondary endpoints that favored MN-166. This was a single center, double blind, placebo controlled six-month study with patients randomized 2:1 to receive riluzole (100 mg/day) plus either MN-166 (60 mg/day) or placebo. The six-month double blind portion was followed by a six-month open label extension phase during which all patients received MN-166.
Biotech company MediciNova Inc. said late Thursday that it had received positive top-line results from the company's clinical trial of MN-166 in amyotrophic lateral sclerosis. Shares went on a rampage ...
MediciNova Inc (NASDAQ:MNOV), a USD$251.26M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoingRead More...
MediciNova Inc (NASDAQ:MNOV), a biotechnology company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM. As aRead More...
On June 5, 2017, MediciNova (MNOV) announced that Professor Kerrie McDonald presented results from a preclinical study of MN-166 (ibudilast) in the treatment of glioblastoma (GBM) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Proteomic profiling of samples from 30 GBM patients revealed macrophage inhibitory factor (MIF) as a protein that was expressed in “poor responders” (e.g., those that lived
There have been a number of recent announcements regarding MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS), which is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain and spinal cord that control muscle movement degenerate. - On February 7, 2017, MediciNova, Inc. (MNOV) announced that an abstract regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology (AAN) 69th Annual Meeting, which is taking place from Apr. 22-28, 2017 in Boston, Massachusetts. - On December 20, 2016, MediciNova announced that the European Commission has granted Orphan Medicinal Product Designation (OMPD) for MN-166 for the treatment of ALS.